Calycosin

Calycosin at a Glance

Calycosin is the best-known isoflavone of astragalus (Astragalus membranaceus, huang qi). Structurally it is 3’-hydroxyformononetin — the hydroxylated sibling of formononetin — and, together with its sugar-bound form calycosin-7-O-glucoside, it is one of the marker compounds the Chinese Pharmacopoeia uses to certify astragalus root ^{1,11Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →Reference 11Dai Y et al. · 2020Quality markers for Astragali Radix and its products based on process analysis — analytical / QCView study →}.

Like other isoflavones it is a phytoestrogen, but a selective one: its distinctive pharmacology runs through estrogen receptor β (ERβ) rather than ERα, and this ERβ route is the mechanism behind its most-studied effect — an anti-proliferative action on breast-cancer cells ^{2,3Reference 2Chen J et al. · 2014In vitroCalycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways — in vitroView study →Reference 3Chen J et al. · 2013In vitroEstrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin — in vitroView study →}. It is separately noted for a pro-angiogenic action (promoting new blood-vessel growth, of interest for wounds and ischaemia but a double-edge in cancer) ^{6Reference 6Tang JY et al. · 2010In vitroCalycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC — in vitro / zebrafishView study →} and for neuroprotection in stroke models ^{7,8Reference 7Wang Y et al. · 2018AnimalNeuroprotective mechanisms of calycosin against focal cerebral ischemia and reperfusion injury in rats — rat in vivoView study →Reference 8Yang X et al. · 2024In vitroCalycosin ameliorates neuroinflammation via TLR4-mediated signal following cerebral ischemia/reperfusion injury in vivo and in vitro — rat in vivo / in vitroView study →}.

The honest frame for the whole page: this is a large but almost entirely preclinical literature on the isolated molecule in cells and rodents. Calycosin is extensively glucuronidated, so systemic levels of the free aglycone are low, and no isolated-compound human trial exists — human evidence for astragalus is whole-extract and does not transfer to calycosin specifically ^{1,10Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →Reference 10Ruan JQ · 2014In vitroRegioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases — in vitro metabolismView study →}.

Calycosin & Estrogen Receptor β

The feature that sets calycosin apart from a generic antioxidant flavonoid is that it behaves as a selective estrogen-receptor-β agonist. Estrogen has two main receptors — ERα, which tends to drive proliferation in breast tissue, and ERβ, which tends to oppose it — and calycosin’s activity is consistently reported to depend on the β receptor.

The clearest evidence is in breast-cancer cells. In ER-positive lines (MCF-7, T-47D), the isolated molecule inhibited proliferation and triggered apoptosis in a dose-dependent way, and the effect was ERβ-dependent: it worked through ERβ-mediated regulation of IGF-1R signalling, p38 MAPK and the PI3K/Akt pathway (with miR-375 involvement), and was lost when ERβ was blocked ^{2Reference 2Chen J et al. · 2014In vitroCalycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways — in vitroView study →}. A companion study found both calycosin and its sibling formononetin drove ERβ-mediated growth inhibition and apoptosis, with calycosin the more potent of the two ^{3Reference 3Chen J et al. · 2013In vitroEstrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin — in vitroView study →}. Later work extended the anti-cancer signal beyond the classical receptors — to membrane GPR30 (GPER) via WDR7-7 ^{4Reference 4Tian J et al. · 2017In vitroCalycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 signaling — in vitro / xenograftView study →} and, in triple-negative disease, to down-regulation of the ER-α30 splice variant–driven PI3K/AKT axis ^{5Reference 5Li Y et al. · 2023In vitroCalycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway — in vitro / in vivoView study →}.

This is also where the phytoestrogen double nature matters. Isoflavones are classic biphasic agents — at low, physiologic concentrations they can act as weak estrogens (potentially proliferative), while at the higher concentrations used in these experiments they are anti-proliferative. In the published breast-cancer work the net isolate effect was inhibitory via ERβ ^{2,3,4Reference 2Chen J et al. · 2014In vitroCalycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways — in vitroView study →Reference 3Chen J et al. · 2013In vitroEstrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin — in vitroView study →Reference 4Tian J et al. · 2017In vitroCalycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 signaling — in vitro / xenograftView study →}, but the dual, dose-dependent character is exactly why isolated-isoflavone effects in hormone-sensitive tissue should not be assumed benign at every exposure — a caution that belongs to the whole phytoestrogen class, calycosin included.

The Astragalus Isoflavone Marker

Calycosin is inseparable from the identity of astragalus as a herb. Astragalus root is standardised on two chemotypes of marker compound: the cycloartane saponin astragaloside IV, and the isoflavone calycosin — specifically its glycoside calycosin-7-O-glucoside (calycosin-7-O-β-D-glucoside). Both the glucoside and astragaloside IV are the compounds the Chinese Pharmacopoeia names to quality-control the root and its products ^{1,11Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →Reference 11Dai Y et al. · 2020Quality markers for Astragali Radix and its products based on process analysis — analytical / QCView study →}.

There is a practical wrinkle in using the glucoside as the marker: calycosin-7-O-glucoside is chemically unstable during processing and storage — malic-acid esters of it decompose to the glucoside, and the glucoside can itself lose its sugar — which is why analysts have argued the free aglycone calycosin, which stays stable through manufacture, is the more reliable quality marker ^{11Reference 11Dai Y et al. · 2020Quality markers for Astragali Radix and its products based on process analysis — analytical / QCView study →}.

Its relationship to formononetin is structural and biosynthetic. Calycosin is 3’-hydroxyformononetin: formononetin bears a single 4’-methoxy group on the B-ring, and adding a hydroxyl at the 3’ position — the reaction of an isoflavone 3’-hydroxylase — converts formononetin into calycosin. The two co-occur in astragalus and share a weak-phytoestrogen profile, but the extra 3’-OH gives calycosin its own hydrogen-bonding, antioxidant and ERβ-binding character. Both are secondary to astragaloside IV and the astragalus polysaccharides by study volume ^{1Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →}.

What It's Used For

The evidence is broad in topic but narrow in tier: isolated-molecule experiments, overwhelmingly in cells and rodents, aggregated in a dedicated review ^{1Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →}. Read each row for what it actually rests on — and remember the pharmacokinetic ceiling (low circulating aglycone) that sits under all of it.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume, tempered for isolate-vs-plant match and bioavailability. A beta, not a validated metric. Every score here is capped by the same ceiling: no isolated-compound human trial, and low systemic exposure of the free aglycone. Each application links to its write-up.

01Anti-breast-cancer (ERβ)Shaky40%Multiple ER+/TNBC cell lines + some xenograft, coherent ERβ mechanism ^{2,3,4,5Reference 2Chen J et al. · 2014In vitroCalycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways — in vitroView study →Reference 3Chen J et al. · 2013In vitroEstrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin — in vitroView study →Reference 4Tian J et al. · 2017In vitroCalycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 signaling — in vitro / xenograftView study →Reference 5Li Y et al. · 2023In vitroCalycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway — in vitro / in vivoView study →}

02Pro-angiogenic (wound / ischaemia)Shaky33%HUVEC + zebrafish, VEGF/VEGFR up-regulation via ER/MAPK ^{6Reference 6Tang JY et al. · 2010In vitroCalycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC — in vitro / zebrafishView study →}

03NeuroprotectionShaky29%Rat cerebral ischaemia–reperfusion (MCAO) models ^{7,8Reference 7Wang Y et al. · 2018AnimalNeuroprotective mechanisms of calycosin against focal cerebral ischemia and reperfusion injury in rats — rat in vivoView study →Reference 8Yang X et al. · 2024In vitroCalycosin ameliorates neuroinflammation via TLR4-mediated signal following cerebral ischemia/reperfusion injury in vivo and in vitro — rat in vivo / in vitroView study →}

04Cardiovascular (vasorelaxant / antiplatelet)Shaky24%Rat aorta Ca²⁺-channel block ^{9Reference 9Wu XL et al. · 2006AnimalCalcium channel blocking activity of calycosin, a major active component of Astragali Radix, on rat aorta — ex vivoView study →} + platelet/thrombosis models ^{12Reference 12Li JY et al. · 2026In vitroCalycosin extracted from Astragalus membranaceus root inhibits platelet activation and thrombus formation: insights from in vivo and in vitro experiments — animal / in vitroView study →}

Mechanisms

The through-line is estrogen-receptor signalling: ERβ carries the anti-cancer effect and ER + MAPK helps carry the pro-angiogenic one — the same receptor family pulling in two directions, which is why calycosin reads as both anti-tumour and pro-angiogenic.

Pharmacokinetics

This is the section that caps the whole page. Calycosin’s problem is not getting into cells — it is staying intact in the circulation. The free aglycone permeates reasonably well, but it is a prime substrate for glucuronidation: human liver microsomes and recombinant enzymes conjugate it regioselectively, and UGT1A9 drives formation of calycosin-3’-glucuronide as the dominant metabolite ^{10Reference 10Ruan JQ · 2014In vitroRegioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases — in vitro metabolismView study →}. Intestinal glucuronidation acts before the liver even sees it, so first-pass conjugation is extensive and circulating free-aglycone levels are low ^{1,10Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →Reference 10Ruan JQ · 2014In vitroRegioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases — in vitro metabolismView study →}. The common dietary/herbal input is the glucoside calycosin-7-O-glucoside, which is poorly absorbed intact and is first deglycosylated by gut microbiota to calycosin before any absorption occurs ^{1Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →}. Net result: oral exposure to active free calycosin is small, and the micromolar potencies seen in vitro do not map onto concentrations an oral human dose would reach — the same isolate-vs-reality gap that limits astragaloside IV.

Clinical Trials

There are no registered trials of isolated calycosin. All therapeutic evidence for the molecule is preclinical; human data for astragalus are whole-extract and do not establish anything about the isolated isoflavone ^{1Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

Calycosin sits firmly on the isolate side — and that is both its strength and its limit. Nearly every mechanistic claim above used purified calycosin in cell or rodent systems ^{2,6,9Reference 2Chen J et al. · 2014In vitroCalycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways — in vitroView study →Reference 6Tang JY et al. · 2010In vitroCalycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC — in vitro / zebrafishView study →Reference 9Wu XL et al. · 2006AnimalCalcium channel blocking activity of calycosin, a major active component of Astragali Radix, on rat aorta — ex vivoView study →}, which is why the mechanisms are cleanly attributable to this molecule rather than to a co-acting mixture. The limit is the mirror image: there is no human evidence for the isolate at all. Where astragalus itself has been studied in people, it is as the whole root or a multi-herb formula, in which calycosin is one minor isoflavone alongside astragaloside IV, formononetin, ononin and the astragalus polysaccharides ^{1Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →}. The low systemic exposure of free calycosin ^{10Reference 10Ruan JQ · 2014In vitroRegioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases — in vitro metabolismView study →} means even the whole-plant human data cannot be read as evidence for calycosin specifically — the transfer runs neither from isolate to human nor from herb to molecule.

Prevalence in Nature

Calycosin is characteristically an astragalus isoflavone. It occurs in the root of Astragalus membranaceus (huang qi) — chiefly as the glycoside calycosin-7-O-glucoside, with the free aglycone a minor fraction: measured free-calycosin content across processed root batches ran roughly 0–0.035% of dry weight ^{11Reference 11Dai Y et al. · 2020Quality markers for Astragali Radix and its products based on process analysis — analytical / QCView study →}. It is also reported in other Astragalus species and, as an isoflavone, is biosynthesised in various legumes (Fabaceae) that carry the isoflavonoid pathway. Within astragalus it is quantitatively secondary to the cycloartane saponins (astragaloside IV) and the polysaccharide fraction, but as a marker for identity and quality it is central ^{1,11Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →Reference 11Dai Y et al. · 2020Quality markers for Astragali Radix and its products based on process analysis — analytical / QCView study →}.

Its place in the plant’s chemistry is defined by one biosynthetic step: the isoflavonoid pathway builds formononetin first, and an isoflavone 3’-hydroxylase adds the 3’-hydroxyl that turns formononetin into calycosin — so the two always travel together, with calycosin downstream.

Discovery & Synthesis

Calycosin (CAS 20575-57-9) is 7,3’-dihydroxy-4’-methoxyisoflavone, long characterised as one of the isoflavones of astragalus and structurally the 3’-hydroxy analogue of formononetin. Its early history is bound up with the phytochemical work-up of Astragalus membranaceus, where it and its glucoside were identified as the isoflavone markers of the root ^{1,11Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →Reference 11Dai Y et al. · 2020Quality markers for Astragali Radix and its products based on process analysis — analytical / QCView study →}. Biosynthetically it is not made de novo but derived from formononetin by isoflavone 3’-hydroxylation; the first total chemical synthesis is not well documented, and calycosin is obtained for research overwhelmingly by extraction and purification from astragalus root (or by enzymatic/microbial deglycosylation of the more abundant calycosin-7-O-glucoside) rather than by manufacture from scratch.

Patents: not yet researched.

Toxicity & Safety

Calycosin carries a low flag: it is a dietary-type isoflavone consumed for centuries as part of whole astragalus, its free-aglycone systemic exposure is intrinsically low because of extensive glucuronidation ^{10Reference 10Ruan JQ · 2014In vitroRegioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases — in vitro metabolismView study →}, and reviews of the isolated compound describe a broadly favourable preclinical safety profile ^{1Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →}. The meaningful cautions are not general toxicity but two mechanism-specific double-edges.

The first is phytoestrogenic. Calycosin is a selective ERβ phytoestrogen with biphasic, dose-dependent behaviour: anti-proliferative in the higher-concentration cancer studies ^{2,3Reference 2Chen J et al. · 2014In vitroCalycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways — in vitroView study →Reference 3Chen J et al. · 2013In vitroEstrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin — in vitroView study →}, but as a member of the isoflavone class its low-dose estrogenic character means concentrated isoflavone intake is a reasonable point of individual caution in hormone-sensitive conditions, and any reproductive/developmental consideration for an isolated phytoestrogen is a whole-preparation decision made on the herb or product page, not settled here. The second is pro-angiogenic: because calycosin up-regulates VEGF and promotes new vessel growth ^{6Reference 6Tang JY et al. · 2010In vitroCalycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC — in vitro / zebrafishView study →}, the same property that is attractive for wound healing is a theoretical concern where new blood-vessel growth is unwanted (established or angiogenesis-dependent tumours). Documented human drug-interaction data for the isolated molecule are lacking; the antiplatelet/GPVI signal ^{12Reference 12Li JY et al. · 2026In vitroCalycosin extracted from Astragalus membranaceus root inhibits platelet activation and thrombus formation: insights from in vivo and in vitro experiments — animal / in vitroView study →} is preclinical, but is the most plausible place a future interaction (with anticoagulants/antiplatelets) would be looked for.

Safety at a Glance

✅ Low / no toxicity

• Low intrinsic toxicity. A dietary-type isoflavone from whole astragalus, with low free-aglycone systemic exposure due to extensive glucuronidation.
• Selective phytoestrogen. ERβ-selective and biphasic — concentrated isoflavone intake warrants individual caution in hormone-sensitive conditions; reproductive decisions belong to the herb/product page.
• Pro-angiogenic double-edge. Up-regulates VEGF/new-vessel growth — useful for wounds/ischaemia but a theoretical concern in angiogenesis-dependent cancer.
• Preclinical antiplatelet signal. A GPVI-mediated antiplatelet/antithrombotic effect (rodent) is the most likely site of a future interaction with blood-thinning drugs; not established in people.

Dosage

There is no established human dose for isolated calycosin, and its poor systemic exposure means research doses do not translate into an oral human regimen. Human exposure occurs as one minor isoflavone within whole astragalus preparations, standardised (where standardised at all) to calycosin-7-O-glucoside and astragaloside IV rather than to free calycosin ^{1,11Reference 1Gong G et al. · 2021ReviewPharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — reviewView study →Reference 11Dai Y et al. · 2020Quality markers for Astragali Radix and its products based on process analysis — analytical / QCView study →}. For research context only, the studies above used purified calycosin in cell culture (typically low-micromolar concentrations) and, in rodent stroke/cardiovascular models, dosing by injection or gavage — routes and levels not achievable by ordinary oral intake ^{7,9Reference 7Wang Y et al. · 2018AnimalNeuroprotective mechanisms of calycosin against focal cerebral ischemia and reperfusion injury in rats — rat in vivoView study →Reference 9Wu XL et al. · 2006AnimalCalcium channel blocking activity of calycosin, a major active component of Astragali Radix, on rat aorta — ex vivoView study →}. These are doses studied in research and are not a personal recommendation.

References

1. Gong G, Zheng Y, Yang Y, Sui Y, Wen Z (2021). Pharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus — review. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/34035829/
2. Chen J, Hou R, Zhang X, Ye Y, Wang Y, Tian J (2014). Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways — in vitro. PLoS One. https://pubmed.ncbi.nlm.nih.gov/24618835/
3. Chen J, Zhao X, Ye Y, Wang Y, Tian J (2013). Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin — in vitro. Cellular Physiology and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/24355881/
4. Tian J, Wang Y, Zhang X, Ren Q, Li R, Huang Y, Lu H, Chen J (2017). Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 signaling — in vitro / xenograft. Journal of Experimental & Clinical Cancer Research. https://pubmed.ncbi.nlm.nih.gov/29096683/
5. Li Y, Hu S, Chen Y, Zhang X, Gao H, Tian J, Chen J (2023). Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway — in vitro / in vivo. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/37393829/
6. Tang JY, Li S, Li ZH, Zhang ZJ, Hu G, Cheang LCV, Alex D, Hoi MPM, Kwan YW, Chan SW, Leung GPH, Lee SMY (2010). Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC — in vitro / zebrafish. PLoS One. https://pubmed.ncbi.nlm.nih.gov/20686605/
7. Wang Y, Ren Q, Zhang X, Lu H, Chen J (2018). Neuroprotective mechanisms of calycosin against focal cerebral ischemia and reperfusion injury in rats — rat in vivo. Cellular Physiology and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/29402799/
8. Yang X, Pan Y, Cai L, Wang W, Zhai X, Zhang Y, Wu Q, Chen J, Zhang C, Wang Y (2024). Calycosin ameliorates neuroinflammation via TLR4-mediated signal following cerebral ischemia/reperfusion injury in vivo and in vitro — rat in vivo / in vitro. Journal of Inflammation Research. https://pubmed.ncbi.nlm.nih.gov/39677283/
9. Wu XL, Wang YY, Cheng J, Zhao YY (2006). Calcium channel blocking activity of calycosin, a major active component of Astragali Radix, on rat aorta — ex vivo. Acta Pharmacologica Sinica. https://pubmed.ncbi.nlm.nih.gov/16867251/
10. Ruan JQ, Yan R (2014). Regioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases — in vitro metabolism. Chemico-Biological Interactions. https://pubmed.ncbi.nlm.nih.gov/25044472/
11. Dai Y, Wang D, Zhao M, Yan L, Zhu C, Li P, Qin X, Verpoorte R, Chen S (2020). Quality markers for Astragali Radix and its products based on process analysis — analytical / QC. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/33390938/
12. Li JY, Lin KH, Chen TY, Chen RJ, Wang HH, Peng HY, Lu WJ (2026). Calycosin extracted from Astragalus membranaceus root inhibits platelet activation and thrombus formation: insights from in vivo and in vitro experiments — animal / in vitro. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/41633254/

View all 12 references▾